<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860574</url>
  </required_header>
  <id_info>
    <org_study_id>2272.00</org_study_id>
    <secondary_id>NCI-2010-00315</secondary_id>
    <secondary_id>P01HL036444</secondary_id>
    <nct_id>NCT00860574</nct_id>
  </id_info>
  <brief_title>Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Multi-Center Study of Conditioning With Treosulfan, Fludarabine and Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS), and Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving treosulfan together with fludarabine&#xD;
      phosphate and total-body irradiation followed by donor stem cell transplant works in treating&#xD;
      patients with high-risk acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic&#xD;
      leukemia. Giving chemotherapy, such as treosulfan and fludarabine phosphate, and total-body&#xD;
      irradiation before a donor bone marrow or peripheral blood stem cell transplant helps stop&#xD;
      the growth of cancer cells. It may also stop the patient's immune system from rejecting the&#xD;
      donor's stem cells. The donated stem cells may replace the patient's immune cells and help&#xD;
      destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted&#xD;
      cells from a donor can also make an immune response against the body's normal cells. Giving&#xD;
      tacrolimus and methotrexate before and after transplant may stop this from happening&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Decrease the incidence of relapse to &lt; 15% at 6 month post transplant in patients with&#xD;
      high risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) transplanted from&#xD;
      related or unrelated donors, without unacceptably increasing toxicity (10% non-relapse&#xD;
      mortality [NRM] at 6 months).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the incidence of NRM at 180 days and 1 year after hematopoietic cell&#xD;
      transplantation (HCT).&#xD;
&#xD;
      II. Evaluate overall survival (OS) and relapse-free survival (RFS). III. Incidence of grades&#xD;
      II-IV acute graft-versus-host disease (GVHD). IV. Incidence of chronic GVHD. V. Donor&#xD;
      chimerism on days +28 and +100.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) over 30&#xD;
      minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients&#xD;
      also undergo total-body irradiation on day 0.&#xD;
&#xD;
      TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or&#xD;
      bone marrow transplantation on day 0.&#xD;
&#xD;
      GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally (PO) twice daily&#xD;
      (BID) on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients&#xD;
      also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse Incidence</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Non Relapse Mortality (NRM) Incidence</measure>
    <time_frame>At 6 months</time_frame>
    <description>Cumulative incidence of NRM at 6 months. NRM includes all deaths without relapse or disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non Relapse Mortality Incidence</measure>
    <time_frame>1 year after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free Survival</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grades II-IV Acute GVHD</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Chronic GVHD</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Donor CD3 + T Lymphocyte Chimerism in Peripheral Blood</measure>
    <time_frame>Day 28 after HCT</time_frame>
    <description>Donor chimerism was evaluated in peripheral blood T cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
  <condition>Adult Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Childhood Acute Myeloid Leukemia in Remission</condition>
  <condition>Childhood Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Secondary Myelodysplastic Syndromes</condition>
  <condition>Untreated Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (allogeneic transplantation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treosulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (allogeneic transplantation)</arm_group_label>
    <other_name>dihydroxybusulfan</other_name>
    <other_name>Ovastat</other_name>
    <other_name>tresulfon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (allogeneic transplantation)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Low dose starting at 2Gy</description>
    <arm_group_label>Treatment (allogeneic transplantation)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Given IV per institutional standard practice</description>
    <arm_group_label>Treatment (allogeneic transplantation)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (allogeneic transplantation)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <description>Given IV per institutional standard practice</description>
    <arm_group_label>Treatment (allogeneic transplantation)</arm_group_label>
    <other_name>bone marrow therapy, allogeneic</other_name>
    <other_name>bone marrow therapy, allogenic</other_name>
    <other_name>transplantation, allogeneic bone marrow</other_name>
    <other_name>transplantation, allogenic bone marrow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Given IV per institutional standard practice</description>
    <arm_group_label>Treatment (allogeneic transplantation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (allogeneic transplantation)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute myeloid leukemia (AML):&#xD;
&#xD;
               -  All AML patients beyond 1st remission;&#xD;
&#xD;
               -  Intermediate or high risk AML patients (based on South West Oncology Group [SWOG]&#xD;
                  cytogenetic criteria) in 1st complete remission&#xD;
&#xD;
          -  Myelodysplastic syndrome (MDS)&#xD;
&#xD;
          -  Other myeloid malignancies as chronic myelogenous leukemia (CML), CML accelerated&#xD;
             phase, CML blast crisis, chronic myelomonocytic leukemia (CMML) (to be approved by&#xD;
             patient care conference [PCC])&#xD;
&#xD;
          -  With Karnofsky Index or Lansky Play-Performance Scale &gt; 70% on pre-transplant&#xD;
             evaluation&#xD;
&#xD;
          -  Able to give informed consent (if &gt; 18 years), or with a legal guardian capable of&#xD;
             giving informed consent (if &lt; 18 years)&#xD;
&#xD;
          -  Previous autologous or allogeneic HCT is allowed&#xD;
&#xD;
          -  Donors must be:&#xD;
&#xD;
               -  Human leukocyte antigen (HLA)-identical related donors or&#xD;
&#xD;
               -  Unrelated donors matched for HLA-A, B, C, DRB1, and DQB1 defined by high&#xD;
                  resolution deoxyribonucleic acid (DNA) typing or mismatched for one HLA allele,&#xD;
                  except for HLA-C where no mismatch is allowed&#xD;
&#xD;
               -  Able to undergo peripheral blood stem cell collection or bone marrow harvest&#xD;
&#xD;
               -  In good general health, with a Karnofsky or Lansky Play Performance score &gt; 90%&#xD;
&#xD;
               -  Able to give informed consent (if &gt; 18 years), or with a legal guardian capable&#xD;
                  of giving informed consent (if &lt; 18 years)&#xD;
&#xD;
          -  Acute lymphoblastic leukemia (ALL): all ALL patients not eligible for other protocols&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving umbilical cord blood&#xD;
&#xD;
          -  With impaired cardiac function as evidenced by ejection fraction &lt; 35% or cardiac&#xD;
             insufficiency requiring treatment or symptomatic coronary artery disease&#xD;
&#xD;
          -  With impaired pulmonary function as evidenced by partial pressure of oxygen (pO2) &lt; 70&#xD;
             mm Hg and diffusing capacity of the lung for carbon monoxide (DLCO) &lt; 70% of predicted&#xD;
             or pO2 &lt; 80 mm Hg and DLCO &lt; 60% of predicted; or receiving supplementary continuous&#xD;
             oxygen&#xD;
&#xD;
          -  With impaired renal function as evidenced by creatinine-clearance &lt; 50% for age,&#xD;
             weight, height or serum creatinine &gt; 2x upper normal limit or dialysis-dependent&#xD;
&#xD;
          -  With hepatic dysfunction as evidenced by total bilirubin or aspartate aminotransferase&#xD;
             (AST) or alanine aminotransferase (ALT) &gt; 2.0 x upper normal limit or evidence of&#xD;
             synthetic dysfunction or severe cirrhosis&#xD;
&#xD;
          -  With active infectious disease requiring deferral of conditioning, as recommended by&#xD;
             an Infectious Disease specialist&#xD;
&#xD;
          -  With human immunodeficiency virus (HIV)-positivity or active infectious hepatitis&#xD;
             because of possible risk of lethal infection when treated with immunosuppressive&#xD;
             therapy&#xD;
&#xD;
          -  With central nervous system (CNS) leukemic involvement not clearing with intrathecal&#xD;
             chemotherapy and/or cranial radiation prior to initiating conditioning (day -6)&#xD;
&#xD;
          -  With life expectancy severely limited by diseases other than malignancy&#xD;
&#xD;
          -  Women who are pregnant or lactating because of possible risk to the fetus or infant&#xD;
&#xD;
          -  With known hypersensitivity to treosulfan and/or fludarabine&#xD;
&#xD;
          -  Receiving another experimental drug within 4 weeks before initiation of conditioning&#xD;
             (day -6)&#xD;
&#xD;
          -  Unable to give informed consent (if &gt; 18 years) or with a legal guardian (if &lt; 18&#xD;
             years) unable to give informed consent&#xD;
&#xD;
          -  Ineligible donors will be those:&#xD;
&#xD;
               -  Deemed unable to undergo marrow harvesting or PBSC mobilization and leukapheresis&#xD;
&#xD;
               -  Who are HIV-positive&#xD;
&#xD;
               -  With active infectious hepatitis&#xD;
&#xD;
               -  Females with a positive pregnancy test&#xD;
&#xD;
               -  Unable to give informed consent (if &gt; 18 years) or with a legal guardian (if &lt; 18&#xD;
                  years) unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boglarka Gyurkocza</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80217-3364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <results_first_submitted>February 9, 2021</results_first_submitted>
  <results_first_submitted_qc>February 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2021</results_first_posted>
  <disposition_first_submitted>April 5, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>April 5, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 7, 2017</disposition_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Joachim Deeg</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Allogeneic Transplantation)</title>
          <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
treosulfan: Given IV&#xD;
fludarabine phosphate: Given IV&#xD;
total-body irradiation: Low dose starting at 2Gy&#xD;
peripheral blood stem cell transplantation: Given IV per institutional standard practice&#xD;
tacrolimus: Given IV or PO&#xD;
allogeneic bone marrow transplantation: Given IV per institutional standard practice&#xD;
allogeneic hematopoietic stem cell transplantation: Given IV per institutional standard practice&#xD;
methotrexate: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relapse</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Allogeneic Transplantation)</title>
          <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6 and 11.&#xD;
treosulfan: Given IV&#xD;
fludarabine phosphate: Given IV&#xD;
total-body irradiation: Low dose starting at 2Gy&#xD;
peripheral blood stem cell transplantation: Given IV per institutional standard practice&#xD;
tacrolimus: Given IV or PO&#xD;
allogeneic bone marrow transplantation: Given IV per institutional standard practice&#xD;
allogeneic hematopoietic stem cell transplantation: Given IV per institutional standard practice&#xD;
methotrexate: Given IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" lower_limit="1" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relapse Incidence</title>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Allogeneic Transplantation)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
treosulfan: Given IV&#xD;
fludarabine phosphate: Given IV&#xD;
total-body irradiation: Low dose starting at 2Gy&#xD;
peripheral blood stem cell transplantation: Given IV per institutional standard practice&#xD;
tacrolimus: Given IV or PO&#xD;
allogeneic bone marrow transplantation: Given IV per institutional standard practice&#xD;
allogeneic hematopoietic stem cell transplantation: Given IV per institutional standard practice&#xD;
methotrexate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Incidence</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non Relapse Mortality (NRM) Incidence</title>
        <description>Cumulative incidence of NRM at 6 months. NRM includes all deaths without relapse or disease progression.</description>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Allogeneic Transplantation)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
treosulfan: Given IV&#xD;
fludarabine phosphate: Given IV&#xD;
total-body irradiation: Low dose starting at 2Gy&#xD;
peripheral blood stem cell transplantation: Given IV per institutional standard practice&#xD;
tacrolimus: Given IV or PO&#xD;
allogeneic bone marrow transplantation: Given IV per institutional standard practice&#xD;
allogeneic hematopoietic stem cell transplantation: Given IV per institutional standard practice&#xD;
methotrexate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Non Relapse Mortality (NRM) Incidence</title>
          <description>Cumulative incidence of NRM at 6 months. NRM includes all deaths without relapse or disease progression.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non Relapse Mortality Incidence</title>
        <time_frame>1 year after HCT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Allogeneic Transplantation)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
treosulfan: Given IV&#xD;
fludarabine phosphate: Given IV&#xD;
total-body irradiation: Low dose starting at 2Gy&#xD;
peripheral blood stem cell transplantation: Given IV per institutional standard practice&#xD;
tacrolimus: Given IV or PO&#xD;
allogeneic bone marrow transplantation: Given IV per institutional standard practice&#xD;
allogeneic hematopoietic stem cell transplantation: Given IV per institutional standard practice&#xD;
methotrexate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Non Relapse Mortality Incidence</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <time_frame>at 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Allogeneic Transplantation)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
treosulfan: Given IV&#xD;
fludarabine phosphate: Given IV&#xD;
total-body irradiation: Low dose starting at 2Gy&#xD;
peripheral blood stem cell transplantation: Given IV per institutional standard practice&#xD;
tacrolimus: Given IV or PO&#xD;
allogeneic bone marrow transplantation: Given IV per institutional standard practice&#xD;
allogeneic hematopoietic stem cell transplantation: Given IV per institutional standard practice&#xD;
methotrexate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse-free Survival</title>
        <time_frame>at 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Allogeneic Transplantation)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
treosulfan: Given IV&#xD;
fludarabine phosphate: Given IV&#xD;
total-body irradiation: Low dose starting at 2Gy&#xD;
peripheral blood stem cell transplantation: Given IV per institutional standard practice&#xD;
tacrolimus: Given IV or PO&#xD;
allogeneic bone marrow transplantation: Given IV per institutional standard practice&#xD;
allogeneic hematopoietic stem cell transplantation: Given IV per institutional standard practice&#xD;
methotrexate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse-free Survival</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grades II-IV Acute GVHD</title>
        <time_frame>at 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Allogeneic Transplantation)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
treosulfan: Given IV&#xD;
fludarabine phosphate: Given IV&#xD;
total-body irradiation: Low dose starting at 2Gy&#xD;
peripheral blood stem cell transplantation: Given IV per institutional standard practice&#xD;
tacrolimus: Given IV or PO&#xD;
allogeneic bone marrow transplantation: Given IV per institutional standard practice&#xD;
allogeneic hematopoietic stem cell transplantation: Given IV per institutional standard practice&#xD;
methotrexate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grades II-IV Acute GVHD</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Chronic GVHD</title>
        <time_frame>at 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Allogeneic Transplantation)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
treosulfan: Given IV&#xD;
fludarabine phosphate: Given IV&#xD;
total-body irradiation: Low dose starting at 2Gy&#xD;
peripheral blood stem cell transplantation: Given IV per institutional standard practice&#xD;
tacrolimus: Given IV or PO&#xD;
allogeneic bone marrow transplantation: Given IV per institutional standard practice&#xD;
allogeneic hematopoietic stem cell transplantation: Given IV per institutional standard practice&#xD;
methotrexate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Chronic GVHD</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Donor CD3 + T Lymphocyte Chimerism in Peripheral Blood</title>
        <description>Donor chimerism was evaluated in peripheral blood T cells</description>
        <time_frame>Day 28 after HCT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Allogeneic Transplantation)</title>
            <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
treosulfan: Given IV&#xD;
fludarabine phosphate: Given IV&#xD;
total-body irradiation: Low dose starting at 2Gy&#xD;
peripheral blood stem cell transplantation: Given IV per institutional standard practice&#xD;
tacrolimus: Given IV or PO&#xD;
allogeneic bone marrow transplantation: Given IV per institutional standard practice&#xD;
allogeneic hematopoietic stem cell transplantation: Given IV per institutional standard practice&#xD;
methotrexate: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Median Donor CD3 + T Lymphocyte Chimerism in Peripheral Blood</title>
          <description>Donor chimerism was evaluated in peripheral blood T cells</description>
          <units>percentage of T cells</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="88" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Toxicities Before Day 100</time_frame>
      <desc>Toxicities documented per Common Terminology Criteria for Adverse Events (CTCAE) v3.0</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Allogeneic Transplantation)</title>
          <description>CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6 and 11.&#xD;
treosulfan: Given IV&#xD;
fludarabine phosphate: Given IV&#xD;
total-body irradiation: Low dose starting at 2Gy&#xD;
peripheral blood stem cell transplantation: Given IV per institutional standard practice&#xD;
tacrolimus: Given IV or PO&#xD;
allogeneic bone marrow transplantation: Given IV per institutional standard practice&#xD;
allogeneic hematopoietic stem cell transplantation: Given IV per institutional standard practice&#xD;
methotrexate: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Gut GVHD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Liver failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>AST 2680</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial/sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>VRE bacteremia/sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Disseminated toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteremia/VRE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>CMV pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Aspirgillus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hypoglycemia w/seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney rejection - pre-existing hx kidney transplant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Renal failure/dialysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome (ARDS)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hypoxia/resp failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Intubated secondary to DAH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Respiratory failure/intubated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Cardiac arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pul.Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Diffuse alveolar hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura (TTP) coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>LVEF 35%</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal central vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Mucosi</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Proximal myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Steroid induced DM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>LE weakness/deconditioning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT/AST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>t.bili 4.2</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Elevated ferritin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Steroid myopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathic leg pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Peripheral neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome (PRES)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Acute renal failure/creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Renal failure/acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joachim Deeg</name_or_title>
      <organization>Fred Hutch/University of Washington Cancer Consortium</organization>
      <phone>206.667.5985</phone>
      <email>jdeeg@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

